---
title: "SURMOUNT-1: Tirzepatide Phase 3 Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/surmount-1
source: Primara Labs, markdown mirror of the HTML page
---

# SURMOUNT-1

In SURMOUNT-1, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo (treatment-regimen estimand; Jastreboff AM et al. N Engl J Med 2022;387:205-216).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

Do GLP-1s Cause Muscle Loss? Trial DEXA Data (Philippines)1:50·[Transcript and chapters](https://www.primaralabs.com/videos/glp1-muscle-loss)

## Results

Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ.

## Side effects reported

In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.

| Event | 5 mg | 10 mg | 15 mg | Placebo |
| --- | --- | --- | --- | --- |
| Discontinuation for adverse events | 4.3% | 7.1% | 6.2% | 2.6% |

Design

## Trial design and sources

Compound

Tirzepatide

Phase

3

Population

Adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes

Participants randomised

2,539

Duration

72 weeks

Primary endpoint

Coprimary: percentage change in weight from baseline and weight reduction of 5% or more (week 72)

Estimand

treatment-regimen

Read out

4 June 2022

Treatment-regimen estimand, as the NEJM abstract reports it. Lilly's release (28 April 2022) gave 22.5% on 15 mg under the efficacy estimand; that figure is in lib/trials/tirzepatide.ts for like-for-like comparison with the TRIUMPH releases.

-   Jastreboff AM et al. N Engl J Med 2022;387:205-216 [open](https://doi.org/10.1056/NEJMoa2206038) · checked 23 September 2026
-   ClinicalTrials.gov NCT04184622 [open](https://clinicaltrials.gov/study/NCT04184622) · checked 23 September 2026
-   Registry: NCT04184622

Questions

## SURMOUNT-1, answered

### What did SURMOUNT-1 find?

In SURMOUNT-1, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo (treatment-regimen estimand; Jastreboff AM et al. N Engl J Med 2022;387:205-216).

### What side effects were reported in SURMOUNT-1?

In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.

Related

## More on tirzepatide

-   [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5)
-   [SURMOUNT-2](https://www.primaralabs.com/research/trials/surmount-2)
-   [SURMOUNT-3](https://www.primaralabs.com/research/trials/surmount-3)
-   [SURMOUNT-4](https://www.primaralabs.com/research/trials/surmount-4)
-   [SURMOUNT-5](https://www.primaralabs.com/research/trials/surmount-5)
-   [Evidence Map: Tirzepatide](https://www.primaralabs.com/research/evidence#tirzepatide)
-   [Tirzepatide 15mg](https://www.primaralabs.com/marketplace/tirzepatide-15mg)